Andrew Kuykendall
Hematologist specializing in myeloproliferative neoplasms at Moffitt Cancer Center and recent ASCO plenary presenter for the VERIFY study on polycythemia vera; discusses diagnosis and evolving treatment strategies for PV and ET.
Top 3 podcasts with Andrew Kuykendall
Ranked by the Snipd community
Aug 4, 2025 • 26min
Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, brings his expertise in myeloproliferative neoplasms to a discussion centered on polycythemia vera (PV) and essential thrombocythemia (ET). Key topics include the vital role of JAK2 mutation testing in diagnosis and the latest treatments like ruxolitinib and resveratide. Dr. Kuykendall also emphasizes risk stratification for ET and the importance of managing acquired von Willebrand disease in patients with high platelet counts, showcasing a new era in personalized cancer care.
Sep 2, 2024 • 12min
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Andrew Kuykendall, a doctor from Moffitt Cancer Center, and Lucia Masarova, affiliated with MD Anderson Cancer Center, dive into the complexities of polycythemia vera (PV) and essential thrombocythemia (ET). They discuss unique challenges in treating adolescent and young adult patients, emphasizing personalized treatment strategies. The duo critiques current clinical trials and advocates for collaborative research to improve outcomes. They also explore the feasibility of early interventions and the importance of defining clear treatment goals.
Aug 10, 2023 • 8min
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Experts discuss the mutational landscape and challenges of treating accelerated-phase myeloproliferative neoplasms (MPNs). They highlight the need for novel treatment strategies, including targeted and combination therapies, to improve outcomes.
